Predictive ability of the 3-gene PI in univariate and multivariate Cox regression analyses (AML discovery series)
| Variable . | HR (95% CI) . | P . | β coefficient . |
|---|---|---|---|
| Univariate Cox proportional hazard (OS) | |||
| t(8;21)(q22;q22) | 0.440 (0.277-0.699) | .001 | −0.821 |
| inv(16)(p13q22) | 0.417 (0.262-0.662) | .000 | −0.875 |
| KMT2A rearrangement (11q23) | 1.317 (0.912-1.900) | .142 | 0.275 |
| t(9;11)(p22;q23) | 0.963 (0.554-1.674) | .894 | −0.038 |
| inv(3)(q21q26)/t(3;3)(q21;q26) | 3.200 (1.899-5.392) | .000 | 1.163 |
| NPM1 mutation | 0.811 (0.650-1.012) | .063 | −0.210 |
| FLT3 ITD | 1.561 (1.264-1.930) | .000 | 0.446 |
| CEBPA biallelic mutations | 0.437 (0.246- 0.777) | .005 | −0.828 |
| Age | 1.017 (1.009-1.025) | .000 | 0.017 |
| Cytogenetic risk group (ELN) | 1.678 (1.481-1.902) | .000 | 0.518 |
| PI | 2.718 (2.205-3.351) | .000 | 1.000 |
| WHO performance status | 1.004 (0.936-1.077) | .903 | 0.004 |
| Multivariate Cox proportional hazard (OS) | |||
| t(8;21)(q22;q22) | 0.545 (0.262-1.131) | .103 | −0.607 |
| inv(16)(p13q22) | 0.334 (0.161-0.695) | .003 | −1.095 |
| KMT2A rearrangement (11q23) | 2.342 (1.171-4.680) | .016 | 0.851 |
| t(9;11)(p22;q23) | 0.695 (0.337-1.435) | .325 | −0.364 |
| inv(3)(q21q26)/t(3;3)(q21;q26) | 2.256 (1.138-4.471) | .020 | 0.813 |
| NPM1 mutation | 0.508 (0.282-0.912) | .023 | −0.678 |
| FLT3 ITD | 1.893 (1.078-3.324) | .026 | 0.638 |
| CEBPA biallelic mutations | 0.374 (0.177-0.790) | .010 | −0.984 |
| Age | 1.014 (1.006-1.023) | .000 | 0.014 |
| ELN cytogenetic risk group | 0.790 (0.467-1.335) | .379 | −0.236 |
| PI | 2.002 (1.542-2.601) | .000 | 0.694 |
| WHO performance status | 1.041 (0.969-1.119) | .270 | 0.041 |
| Variable . | HR (95% CI) . | P . | β coefficient . |
|---|---|---|---|
| Univariate Cox proportional hazard (OS) | |||
| t(8;21)(q22;q22) | 0.440 (0.277-0.699) | .001 | −0.821 |
| inv(16)(p13q22) | 0.417 (0.262-0.662) | .000 | −0.875 |
| KMT2A rearrangement (11q23) | 1.317 (0.912-1.900) | .142 | 0.275 |
| t(9;11)(p22;q23) | 0.963 (0.554-1.674) | .894 | −0.038 |
| inv(3)(q21q26)/t(3;3)(q21;q26) | 3.200 (1.899-5.392) | .000 | 1.163 |
| NPM1 mutation | 0.811 (0.650-1.012) | .063 | −0.210 |
| FLT3 ITD | 1.561 (1.264-1.930) | .000 | 0.446 |
| CEBPA biallelic mutations | 0.437 (0.246- 0.777) | .005 | −0.828 |
| Age | 1.017 (1.009-1.025) | .000 | 0.017 |
| Cytogenetic risk group (ELN) | 1.678 (1.481-1.902) | .000 | 0.518 |
| PI | 2.718 (2.205-3.351) | .000 | 1.000 |
| WHO performance status | 1.004 (0.936-1.077) | .903 | 0.004 |
| Multivariate Cox proportional hazard (OS) | |||
| t(8;21)(q22;q22) | 0.545 (0.262-1.131) | .103 | −0.607 |
| inv(16)(p13q22) | 0.334 (0.161-0.695) | .003 | −1.095 |
| KMT2A rearrangement (11q23) | 2.342 (1.171-4.680) | .016 | 0.851 |
| t(9;11)(p22;q23) | 0.695 (0.337-1.435) | .325 | −0.364 |
| inv(3)(q21q26)/t(3;3)(q21;q26) | 2.256 (1.138-4.471) | .020 | 0.813 |
| NPM1 mutation | 0.508 (0.282-0.912) | .023 | −0.678 |
| FLT3 ITD | 1.893 (1.078-3.324) | .026 | 0.638 |
| CEBPA biallelic mutations | 0.374 (0.177-0.790) | .010 | −0.984 |
| Age | 1.014 (1.006-1.023) | .000 | 0.014 |
| ELN cytogenetic risk group | 0.790 (0.467-1.335) | .379 | −0.236 |
| PI | 2.002 (1.542-2.601) | .000 | 0.694 |
| WHO performance status | 1.041 (0.969-1.119) | .270 | 0.041 |
The following categorical and continuous variables were evaluated in univariate Cox proportional hazard models for outcome: age, cytogenetic risk group (1 = favorable, 2 = intermediate, 3 = adverse), prognostic chromosomal abnormalities and molecular lesions, performance status, and PI. HRs > 1 or HRs < 1 indicate, respectively, higher or lower risk of event for higher values of continuous variables and for first category listed for categorical variables in OS models. Bold type denotes statistically significant P values.
CI, confidence interval; ELN, European LeukemiaNet; HR, hazard ratio.